Tiansheng Pharmaceutical Group (002872.SZ) and its subsidiaries' products are expected to be selected for centralized volume purchases by the national alliance for the procurement of traditional Chinese medicine.

Tiansheng Pharmaceutical Group (002872.SZ) announced that the company and its wholly-owned subsidiary Hubei Tiansheng Pharmaceutical Co., Ltd. ("Hubei Tiansheng") participated in the centralized procurement of traditional Chinese medicine by the national alliance. According to the public announcement of the intended selection results of the national alliance for centralized volume procurement of traditional Chinese medicine released by the National Office for Joint Procurement of Traditional Chinese Medicine on December 30, 2024, the company's product Danshen Granules and Hubei Tiansheng's product Xuesaitong Injection are intended to be selected for this centralized procurement.